Tag: Casirivimab
SARS-CoV-2 coronavirus variants B.1.351 and P.1 escape from neutralizing antibodies
“In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. More...